{
    "clinical_study": {
        "@rank": "141116", 
        "arm_group": {
            "arm_group_label": "Prescribers"
        }, 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the effectiveness of the current ticagrelor risk\n      minimisation strategy in Canada through a prescriber knowledge and understanding (KAU)\n      survey of selected important identified safety concerns (i.e., bleeding, dyspnea and drug\n      interactions) and ASA dosage."
        }, 
        "brief_title": "Canadian Ticagrelor Survey", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "Effectiveness of risk minimisation interventions for ticagrelor in Canada"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - N/A (All prescribers will be contacted for participation)\n\n        Exclusion Criteria:\n\n        - Participation in a previous wave of the survey."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All physicians who have prescribed at least one dose of ticargrelor and complete the\n        Knowledge and understanding survey"
            }
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757483", 
            "org_study_id": "D5130L00009"
        }, 
        "intervention_browse": {
            "mesh_term": "Ticagrelor"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 21, 2012", 
        "number_of_groups": "1", 
        "official_title": "Effectiveness of Risk Minimisation Interventions for Ticagrelor in Canada", 
        "overall_official": {
            "affiliation": "Universit\u00e9 de Montr\u00e9al", 
            "last_name": "Yola Moride, PHD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "KAU Questionnaire: Knowledge of the 4 key safety issues pertaining to ticagrelor (adequate or inadequate for each safety issue)", 
            "safety_issue": "Yes", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757483"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "KAU Questionnaire: Practice characteristics", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "KAU Questionnaire: The difference in knowledge of understanding across the key safety concerns", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "KAU Questionnaire: Association between prescribers' characteristics and knowledge and understanding of the key safety concerns.", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "December 2012"
    }
}